[Mechanisms of anti-atherogenic effect of probucol and the prospects of its clinical use].
Lankin
V Z
VZ
Lupanov
V P
VP
Liakishev
A A
AA
Revenko
V M
VM
D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D004341:Drug Evaluation; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000188:drug therapy*; D011341:Probucol / Q000627:therapeutic use*
D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D002784:Cholesterol; D011341:Probucol
Mekhanizmy antiaterogennogo deĭstviia probukola i perspektivy ego klinicheskogo primeneniia.